T1	Participants 520 566	SR patients (localized tumors, volume <100 mL)
T2	Participants 846 891	HR patients (volume >or=100 mL or metastases)
T3	Participants 1161 1173	647 patients
T4	Participants 1198 1212	79 SR patients
T5	Participants 1236 1250	76 SR patients
T6	Participants 1274 1280	240 HR
T7	Participants 1308 1323	252 HR patients